{"nctId":"NCT01318694","briefTitle":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","startDateStruct":{"date":"2011-03"},"conditions":["Hepatitis C"],"count":1081,"armGroups":[{"label":"Treatment Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]},{"label":"Treatment Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]},{"label":"Treatment Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]},{"label":"Treatment Arm D","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Peginterferon alfa-2a","Drug: Ribavirin","Drug: ALV Placebo"]}],"interventions":[{"name":"Alisporivir","otherNames":["DEB025","ALV"]},{"name":"Peginterferon alfa-2a","otherNames":["Pegasys®","PEG"]},{"name":"Ribavirin","otherNames":["Copegus®","RBV"]},{"name":"ALV Placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Chronic HCV infection\n* HCV genotype 1\n* No previous treatment for hepatitis C infection\n* Serum HCV RNA level ≥ 1000 IU/ml assessed by quantitative polymerase chain reaction or equivalent at screening, no upper limit\n* Liver evaluation prior to baseline: liver biopsy within 3 years or Fibroscan within 6 months\n\nExclusion criteria:\n\n* HCV genotype different from genotype 1 or co-infection with other HCV genotype\n* Co-infection with Hepatitis B or HIV\n* Any other cause of relevant liver disease other than HCV\n* Presence or history of hepatic decompensation\n* Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN), more than 1 episode of elevated bilirubin (\\> ULN) in past 6 months\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)","description":"SVR12 was defined as hepatitis C virus (HCV) RNA laboratory value below the level of quantification (\\< LOQ; i.e., 25 IU/ml) 12 weeks after the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"68.9","spread":null},{"groupId":"OG002","value":"69.4","spread":null},{"groupId":"OG003","value":"52.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24)","description":"SVR24 was defined as HCV RNA laboratory value \\< LOQ 24 weeks after the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"69.0","spread":null},{"groupId":"OG002","value":"68.3","spread":null},{"groupId":"OG003","value":"51.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4)","description":"RVR4 was defined as serum HCV RNA \\< LOQ after 4 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null},{"groupId":"OG001","value":"72.5","spread":null},{"groupId":"OG002","value":"56.6","spread":null},{"groupId":"OG003","value":"28.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment","description":"EVR was defined as a ≥ 2 log10 decrease in HCV RNA or HCV RNA \\< LOQ after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"99.6","spread":null},{"groupId":"OG003","value":"89.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment","description":"pEVR was defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ) after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"10.5","spread":null},{"groupId":"OG003","value":"19.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment","description":"cEVR was defined as serum HCV RNA \\< LOQ after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":null},{"groupId":"OG001","value":"96.3","spread":null},{"groupId":"OG002","value":"89.1","spread":null},{"groupId":"OG003","value":"70.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment","description":"eRVR was defined as achieving RVR4 and maintaining HCV RNA \\< LOQ until Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"71.1","spread":null},{"groupId":"OG002","value":"56.7","spread":null},{"groupId":"OG003","value":"28.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks","description":"ETR was defined as serum HCV RNA \\< LOQ at treatment end (completed or prematurely discontinued).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"87.7","spread":null},{"groupId":"OG002","value":"87.5","spread":null},{"groupId":"OG003","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks","description":"ALT abnormalities were summarized as participants who had either:\n\n* ALT \\> 2 x upper limit of normal (ULN) during the study and \\> 2 x ULN at baseline\n* ALT \\> 3 x ULN during the study and \\> 2 x ULN at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"1.9","spread":null},{"groupId":"OG003","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.5","spread":null},{"groupId":"OG003","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks","description":"Grading was according to the Modified Division of Microbiology \\& Infectious Diseases (DMID) Toxicity Tables (version 2.0).\n\nParticipants with multiple abnormalities were counted only once in the worst category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"0.8","spread":null},{"groupId":"OG003","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks","description":"Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"24.7","spread":null},{"groupId":"OG002","value":"23.1","spread":null},{"groupId":"OG003","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"7.2","spread":null},{"groupId":"OG003","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks","description":"Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"21.9","spread":null},{"groupId":"OG002","value":"12.5","spread":null},{"groupId":"OG003","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":273},"commonTop":["Anaemia","Headache","Fatigue","Pyrexia","Neutropenia"]}}}